{"id":"W2123526148","doi":"10.1016/s0140-6736(10)61389-x","title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3284,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Cabazitaxel; Mitoxantrone; Docetaxel; Medicine; Prostate cancer; Prednisone; Internal medicine; Oncology; Taxane; Enzalutamide; Clinical endpoint; Abiraterone acetate; Hazard ratio; Randomized controlled trial; Cancer; Surgery; Chemotherapy; Androgen deprivation therapy; Confidence interval; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}